Vimarsana
Biggest News Aggregation in the World

Anthony Hong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anthony Hong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anthony Hong Today - Breaking & Trending Today

Johnson & Johnson - What is cardiac ablation? - Vimarsana News

Johnson & Johnson - What is cardiac ablation?

For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular...

Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy - Vimarsana News

Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy

Approval based on data from REAL AF Registry, demonstrating value of real-world evidence 

Biosense Webster ablation devices pick up new FDA approvals - Vimarsana News

Biosense Webster ablation devices pick up new FDA approvals

Johnson & Johnson's Biosense Webster announced today that the FDA approved several products in its cardiac ablation portfolio.

Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy - Vimarsana News

Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy

/PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i today announced that several...

First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023 - Vimarsana News

First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

Late breaking analysis of one-year outcomes from the inspIRE clinical study demonstrated early success at the prespecified interim analysis